

### Comments from your Chief Investment Officer

The last day of February marked the third anniversary of the launch of your fund and also the end of another strong month for equity markets. When we launched the fund three years ago, we said it was reasonable to expect our investment strategy to deliver a return of approximately 9% per year, on average, over the long run. We are pleased to report that the returns in the first three years have been a little better than this. Looking into the future we are, if anything, more optimistic than we were three years ago. The pace of innovation remains strong, perhaps even accelerating, and the expansion of global middle class continues apace, all of which should help drive strong economic growth over the coming years and decades. In addition, a resolution to the US-Chinese trade conflict looks to be in sight which should further improve market confidence.


We have made a few minor changes to your portfolio in February, trimming some of the larger positions to make room for a few new investments. You now hold small investments in Edwards Life Sciences, The Cooper Companies and Thermo Fisher Scientific.

### NAV since inception



Net Asset Value Metrics													EUR Class	
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Last NAV	YTD
2019	6.48%	6.02%											130.75	12.88%
2018	6.68%	0.08%	-4.96%	2.12%	6.70%	-2.64%	-0.84%	6.17%	-0.51%	-11.74%	-1.46%	-7.23%	115.83	-9.02%
2017	1.96%	3.06%	1.22%	2.20%	2.74%	-0.48%	2.60%	-0.75%	2.86%	6.24%	3.12%	-2.50%	127.32	24.35%
2016			0.51%	-0.14%	-0.44%	0.83%	4.95%	-0.36%	-0.39%	-4.19%	0.73%	1.09%	102.39	2.39%
Annualized return since inception														9.35%

### Country Allocation



- UNITED STATES ■ FRANCE
- NETHERLANDS ■ SWITZERLAND
- AUSTRALIA ■ CANADA

### Top 10 Holdings

ASML Holding	3.79%
Intuitive Surgical	3.63%
LVMH	3.63%
Fortinet	3.61%
Applied Materials	3.57%
Microsoft	3.51%
Automatic Data Processing	3.49%
Kering	3.48%
Nvidia	3.40%
Roper Technologies	3.37%

### Industry Exposure

Financial Services	12.37%
Software	12.23%
Microelectronic Equipment	10.57%
Microelectronic Manufacturing	7.89%
Luxury Goods	7.11%
Cyber Security	6.28%
Medical Products	6.18%
Medical Technology	5.75%
Telecommunications	5.70%
Diversified Manufacturing	3.37%
Consumer Electronics	3.14%
Insurance	3.13%
Securities Services	2.94%
Consulting	2.83%
Retail	2.65%
Pharmaceuticals	2.45%
Simulation Software	2.16%
Leisure	1.74%
Cosmetics	0.85%
Cash	0.67%

### Portfolio Characteristics\*

Average market. Cap (USD bn)	174.3	Equity Ratio	45.07
Number of Holdings	38	Net Debt/ Op. Cash Flow	-33.68
Sales Growth (5yr)	13%	EPS Growth (5yr)	50%

\*Weighted average of portfolio

## Key fund facts

The Fund aims to deliver capital growth by investing in the equities of resilient, conservatively financed, well managed companies with a proven track record of innovation and growth.

Fund Details		ISIN: GB00BDD1KV12			
Fund Type	UCITS OEIC	Launch Date	29th February 2016	Min. Investment	GBP 10,000
Management Charge*	0.70%	Depositary	HSBC	Min. Further Investment	GBP 5,000
Subscription Charge	0.00%	Auditor	PricewaterhouseCoopers (PWC)	Share Class Availability	NOK, EUR, GBP, USD
Redemption Charge	0.00%	Dealing	Daily (11:00am, UK time)	Fund Domicile	UK
OCF**	1.30%	Pricing	Daily (15:00pm, UK time)	AUM (GBP)	125 million

\*A management fee of 0.7% is charged only on AUM below £350 million. A performance fee of 10% of returns, in excess of the high water mark, is charged only on AUM above £350 million.

\*\* Ongoing Charges to the Fund, as specified in the Key Investor Information Document (KIID) for the specific share class.

### Disclaimer:

These materials contain preliminary information that is subject to change and is not intended to be complete or to constitute all the information necessary to adequately evaluate the consequences of making any investment.

This document is being provided solely for informational purposes. The value of an investment may fall or rise. All investments involve risk and past performance is not a guide to future returns. Equitile offers no guarantee against loss or that investment objectives will be achieved.

Equitile does not offer investment advice. Please read the Key Investor Information Document, Prospectus and any other offer documents carefully and consult with your own legal, accounting, tax and other advisors in order to independently assess the merits of an investment. Investors and any potential investors should be aware of local laws governing investments and should read all the relevant documents including any reports and accounts and scheme particulars as appropriate.

The State of the origin of the Fund is the United Kingdom and the Fund is authorised and regulated by the UK Financial Conduct Authority. This document may only be distributed in or from Switzerland to qualified investors within the meaning of Art. 10 Para. 3, 3bis and 3ter CISA. In Switzerland, the Representative is ACOLIN Fund Services AG, Affolternstrasse 56, CH-8050 Zürich, whilst the Paying agent is Aquila & Co. AG, Bahnhofstrasse 28a, CH – 8001 Zurich. In respect of the units distributed in Switzerland, the competent Courts shall be at the registered office of the Representative in Switzerland. The Basic documents of the Fund as defined in Art. 13a CISO as well as the annual and, if applicable, semi-annual reports may be obtained free of charge at the office of the representative.



Equitile Investments Ltd is authorised and regulated by the UK Financial Conduct Authority.